TG Therapeutics Reports Q2 2026 Financial Results (Press Release)

What Happened
TG Therapeutics, Inc. (TGTX) announced financial results for the three- and six-month periods ended June 30, 2026. The company issued a press release on August 3, 2026 reporting those results and furnished the release as Exhibit 99.1 to a Form 8‑K under Item 2.02 (Results of Operations and Financial Condition). The Form 8‑K provides the press release; the detailed quarterly figures and commentary are contained in that release.

Key Details

• Press release date: August 3, 2026.
• Reporting period: three and six months ended June 30, 2026 (Q2 2026 / year-to-date).
• Filed on Form 8‑K under Item 2.02 and furnished as Exhibit 99.1.
• In accordance with Form 8‑K rules, the press release was furnished (which has different legal filing treatment than information formally "filed").

Why It Matters
The press release contains TG Therapeutics’ latest quarterly financial results and any management commentary included there — key information retail investors use to assess revenue, profitability, cash position and near-term outlook. Investors should read the Exhibit 99.1 press release for the specific numbers (revenue, net income/loss, R&D and SG&A, cash runway or guidance) since the 8‑K itself only furnishes that release. Note the disclosure was furnished rather than filed, which affects how the information is treated under SEC rules.